发明名称 Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
摘要 This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
申请公布号 US9192645(B2) 申请公布日期 2015.11.24
申请号 US201414321572 申请日期 2014.07.01
申请人 University of South Florida 发明人 Cheng Jin Q.;Sebti Said M.
分类号 A61K31/70;A61K31/7052;A61K38/05;A61K31/7076;A61K31/69;A61K31/7064 主分类号 A61K31/70
代理机构 Fanelli Haag PLLC 代理人 Fanelli Haag PLLC
主权项 1. A method for treating a subject having a tumor or cancer, which tumor or cancer overexpresses AKT kinase comprising: a. Confirming whether the tumor or cancer overexpresses AKT kinase and administering to said subject: i. at least one compound of formula I selected from the group consisting of the following compounds: wherein each R2′, R3′, and R5′ is independently hydrogen; optionally substituted phosphate or phosphonate; mono-, di-, or triphosphate; acyl; lower acyl; alkyl; lower alkyl; amide; sulfonate ester; alkyl sulfonate ester; arylalkyl sulfonate ester; sulfonyl; methanesulfonyl; benzyl sulfonyl, wherein the phenyl group of said benzyl is optionally substituted with one or more halo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate; optionally substituted arylsulfonyl; a lipid; phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group that, in vivo, provides a compound of said formula I wherein R2′, R3′ or R5′ is independently H or mono-, di- or tri-phosphate; wherein Rx and Ry are independently hydrogen; optionally substituted phosphate; acyl; lower acyl; amide; alkyl; lower alkyl; aromatic; polyoxyalkylene; polyethyleneglycol; optionally substituted arylsulfonyl; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group; and wherein R1 and R2 each are independently H, optionally substituted straight chained, branched or cyclic alkyl, lower alkyl, alkenyl, or alkynyl, CO-alkyl, CO-alkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, or aralkylsulfonyl wherein the compound of formula I is administered in a dose amount of at least 0.5 mg/m2; ii. a compound of the formula V: wherein R1, R2, R3, R4, and R5 each are independently H, optionally halogenated, substituted straight chained, branched or cyclic alkyl, alkoxyl, alkenyl, or alkynyl, aryl, CO-alkyl, COalkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl; and iii. a pharmaceutically acceptable carrier.
地址 Tampa FL US